Rate My Professor Jenna Gregory

Gregory's research centers on the molecular mechanisms of neurodegenerative diseases, particularly ALS and motor neurone disease, utilizing patient tissues and biofluids to uncover molecular drivers of disease heterogeneity, diagnostic targets, progression markers, and therapeutic opportunities. Her investigations target early pathological changes in non-central nervous system tissues like the gastrointestinal tract and skin, extra-motor symptoms including cognitive dysfunction, neuroinflammation, and molecular crowding. Notable publications include 'RNA aptamer reveals nuclear TDP-43 pathology is an early aggregation event' (Spence et al., Acta Neuropathologica, 2024), 'Protein misfolding enteropathy predicts and prognosticates neurodegenerative disease' (Langerová et al., Gastroenterology, 2026), 'Spatial transcriptomics identifies spatially dysregulated expression of GRM3 and USP47 in ALS' (Gregory et al., Neuropathology and Applied Neurobiology, 2020), and contributions to the MND-SMART trial protocol, the first adaptive multi-arm platform trial for motor neuron disease. She has garnered significant funding, such as the Target ALS Foundation Award ($1,000,000, 2022–2024), NIH Transformative Research Award ($8,400,000, 2021–2026), MRC Equipment Grant (£610,839, 2023), Motor Neurone Disease Association Grant (£200,000, 2022–2024), and others from MND Scotland, Royal Society, and Chan Zuckerberg Initiative. Her work advances precision medicine and early detection strategies in neurodegeneration.